Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression.

BACKGROUND: Geriatric depression with subjective cognitive complaints increases the risk of Alzheimer’s Disease (AD). Memantine is a cognitive enhancer used to treat AD. In a 6-month double-blind randomized placebo-controlled trial of escitalopram and memantine (ESC/MEM), ESC/MEM improved cognition...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Affect Disord
Autors principals: Krause-Sorio, Beatrix, Siddarth, Prabha, Kilpatrick, Lisa, Laird, Kelsey T., Milillo, Michaela M., Ercoli, Linda, Narr, Katherine L., Lavretsky, Helen
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7368564/
https://ncbi.nlm.nih.gov/pubmed/32663977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jad.2020.05.092
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars